logo-loader

Viewing results 101-125 of 192

Health

Can ImmuPharma provide the antidote to me-too failures?

ImmuPharma offers an alternative approach to treating the painful autoimmune disease lupus that has so far been overlooked by the developers of drugs for the condition....

on 10/10/14
Health

ImmuPharma gears up for phase III trials after advanced discussions with potential partner

ImmuPharma said it is preparing to take its lead drug into the final phase of clinical trials after concluding “advanced discussions and detailed due diligence” with an unnamed potential partner....

on 30/9/14
Health

BIG PICTURE - ImmuPharma CEO happy with progress of lead drug candidate

Lupuzor, a breakthrough treatment for the autoimmune disease lupus, has the potential to be a blockbuster. So, in a bid to maximise value, the group is taking a twin track approach to finding a commercial partner....

on 11/9/14
Health

ImmuPharma still advancing lead candidate with blockbuster potential

ImmuPharma is one of those investments where the share price occasionally gets out of step with reality. The five-year chart reveals in 2009 it was trading comfortably above £1 – a price that possibly over-stated its prospects at that time....

on 15/11/13
Health

ImmuPharma investors urged to be patient by Panmure

The City broker Panmure Gordon believes ImmuPharma represents a “significant arbitrage” opportunity at current prices, particularly if it can negotiate breakthrough therapy designation for its lead drug, Lupuzor...

on 19/9/13
Health

ImmuPharma chief excited about the potential of cancer drug

ImmuPharma chief executive Dimitri Dimitriou remains excited and upbeat on the prospects for the company’s IPP-204106 cancer treatment, which is currently undergoing phase I trials...

on 13/8/13
Health

ImmuPharma cancer trial progressing to plan

ImmuPharma said its early stage trial of its potential new cancer treatment is progressing according to plan. Researchers are using what is called a polyplexed Nucant version of IPP-204106, which was shown to be 10 times more efficacious than the original formulation in pre-clinical studies....

on 13/8/13
Health

Update: ImmuPharma gets Lupus treatment boost as US allows smaller final trials

The reduced number of patients means that the cost of the phase III trials will be substantially lower, said the company....

on 31/7/13
Health

Immupharma gets Lupus treatment boost as US allows smaller final trials

The reduced number of patients means that the cost of the phase III trials will be substantially lower, said the company....

on 31/7/13
Health

UPDATE: ImmuPharma strengthens hand with £50mln financing deal

ImmuPharma has agreed a £50mln equity drawdown facility, one of the biggest deals of its kind in London, to fund the late-stage development of Lupuzor, its breakthrough drug for auto-immune disease lupus. The five-year funding package will be provided by Darwin Strategic, owned by Henderson Global Investors....

on 21/5/13
Health

ImmuPharma funding provides "external validation" for drug programme, says broker

ImmuPharma’s £50mln equity funding package agreed with a subsidiary of Henderson Global Investors “mitigates risk” and provides “external validation” for the firm’s plans to take its lead drug into late-stage clinical trials. ...

on 21/5/13
Health

Update: Immupharma explores retention of Lupuzor rights

The company is also still in discussions with a number of potential partners over a licensing deal for Lupuzor....

on 9/4/13